estriol has been researched along with Allergic Encephalomyelitis in 10 studies
hormonin: estrogen replacement; each tablet contains 600 ug micronized 17beta-estradiol, 270 ug estriol and 1.4 mg estrone
chlorapatite : A phosphate mineral with the formula Ca5(PO4)3Cl.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the use of estriol in the treatment of experimental autoimmune encephalomyelitis (EAE) and other cell mediated autoimmune diseases." | 7.70 | Estriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosis. ( Dalal, MA; Kim, S; Liva, SM; Verity, MA; Voskuhl, RR, 1999) |
| "Estriol treatment initiated after disease onset decreased cerebral cortex atrophy." | 5.91 | Neuroprotection in Cerebral Cortex Induced by the Pregnancy Hormone Estriol. ( Farkhondeh, V; Gao, JL; Herbig, PD; Itoh, N; Itoh, Y; MacKenzie-Graham, A; Meyer, CE; Ngo, KH; Nguyen, Q; Oberoi, MR; Padilla-Requerey, AA; Siddarth, P; Smith, AW; Voskuhl, RR, 2023) |
| " Estriol (E3), a pregnancy-specific estrogen, has therapeutic efficacy in MS and EAE, and we evaluated whether E3 could act exclusively through DCs to protect against the inflammatory autoimmune disease EAE." | 3.77 | Estriol generates tolerogenic dendritic cells in vivo that protect against autoimmunity. ( Bedarf, A; Gienapp, IE; McClain, MA; Papenfuss, TL; Powell, ND; Shawler, T; Singh, A; Whitacre, CC, 2011) |
| " This translational study aims to determine whether in vivo treatment with the pregnancy hormone estriol affects MMP-9 levels from immune cells in patients with MS and mice with experimental autoimmune encephalomyelitis (EAE)." | 3.75 | Estrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoimmune demyelinating disease through estrogen receptor alpha (ERalpha). ( Du, S; Gold, SM; Morales, LB; Sasidhar, MV; Sicotte, NL; Tiwari-Woodruff, SK; Voskuhl, RR, 2009) |
| "To evaluate the use of estriol in the treatment of experimental autoimmune encephalomyelitis (EAE) and other cell mediated autoimmune diseases." | 3.70 | Estriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosis. ( Dalal, MA; Kim, S; Liva, SM; Verity, MA; Voskuhl, RR, 1999) |
| "Currently, the cause of MS is unknown." | 2.48 | Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration. ( Spence, RD; Voskuhl, RR, 2012) |
| "Estriol treatment initiated after disease onset decreased cerebral cortex atrophy." | 1.91 | Neuroprotection in Cerebral Cortex Induced by the Pregnancy Hormone Estriol. ( Farkhondeh, V; Gao, JL; Herbig, PD; Itoh, N; Itoh, Y; MacKenzie-Graham, A; Meyer, CE; Ngo, KH; Nguyen, Q; Oberoi, MR; Padilla-Requerey, AA; Siddarth, P; Smith, AW; Voskuhl, RR, 2023) |
| "Estriol treatment prevented decreases in excitatory synaptic transmission and lessened the effect of EAE on PPF." | 1.38 | Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease. ( Avedisian, AA; Dervin, SM; O'Dell, TJ; Voskuhl, RR; Ziehn, MO, 2012) |
| "Estriol was also effective but at doses below those previously established for pregnancy." | 1.31 | Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains. ( Adlard, K; Beam, AG; Bebo, BF; Fyfe-Johnson, A; Offner, H; Vandenbark, AA, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Meyer, CE | 1 |
| Smith, AW | 1 |
| Padilla-Requerey, AA | 1 |
| Farkhondeh, V | 1 |
| Itoh, N | 1 |
| Itoh, Y | 1 |
| Gao, JL | 1 |
| Herbig, PD | 1 |
| Nguyen, Q | 1 |
| Ngo, KH | 1 |
| Oberoi, MR | 1 |
| Siddarth, P | 1 |
| Voskuhl, RR | 7 |
| MacKenzie-Graham, A | 1 |
| Gold, SM | 1 |
| Sasidhar, MV | 1 |
| Morales, LB | 1 |
| Du, S | 1 |
| Sicotte, NL | 1 |
| Tiwari-Woodruff, SK | 1 |
| Papenfuss, TL | 1 |
| Powell, ND | 1 |
| McClain, MA | 1 |
| Bedarf, A | 1 |
| Singh, A | 1 |
| Gienapp, IE | 1 |
| Shawler, T | 1 |
| Whitacre, CC | 1 |
| Spence, RD | 1 |
| Ziehn, MO | 1 |
| Avedisian, AA | 1 |
| Dervin, SM | 1 |
| O'Dell, TJ | 1 |
| Liu, HB | 1 |
| Loo, KK | 2 |
| Palaszynski, K | 1 |
| Ashouri, J | 1 |
| Lubahn, DB | 1 |
| Palaszynski, KM | 1 |
| Liu, H | 1 |
| Kim, S | 1 |
| Liva, SM | 1 |
| Dalal, MA | 1 |
| Verity, MA | 1 |
| Bebo, BF | 1 |
| Fyfe-Johnson, A | 1 |
| Adlard, K | 1 |
| Beam, AG | 1 |
| Vandenbark, AA | 1 |
| Offner, H | 1 |
| Elliott, GA | 1 |
| Gibbons, AJ | 1 |
| Greig, ME | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Combination Trial of Copaxone Plus Estriol in RRMS[NCT00451204] | Phase 2 | 158 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Pilot Trial of Testosterone Treatment for Fatigue in Men With Multiple Sclerosis[NCT03000127] | Phase 2 | 0 participants (Actual) | Interventional | 2018-07-01 | Withdrawn (stopped due to Lack of funding) | ||
| A Double-Blind, Placebo Controlled Trial of Estriol Treatment in Women With Multiple Sclerosis: Effect on Cognition.[NCT01466114] | Phase 2 | 64 participants (Anticipated) | Interventional | 2011-10-31 | Recruiting | ||
| Safety and Tolerability of Oral Two-Doses Estroprogestins Associated With Interferon-Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis[NCT00151801] | Phase 2 | 200 participants | Interventional | 2002-05-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A confirmed relapse was defined as new neurological symptoms or worsening of pre-existing symptoms, lasting at least 48 hours in a subject who had been neurologically stable or improving in the previous 30 days, accompanied by objective change in the neurological examination (worsening of 0.5 points on the EDSS or worsening by 1.0 or more points on the pyramidal, cerebellar, brainstem or visual functional system scores), not due to fatigue alone and not associated with fever or infection. (NCT00451204)
Timeframe: 12 months
| Intervention | relapses per year (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 0.25 |
| Placebo Capsules Plus Copaxone Injections | 0.48 |
A confirmed relapse was defined as new neurological symptoms or worsening of pre-existing symptoms, lasting at least 48 hours in a subject who had been neurologically stable or improving in the previous 30 days, accompanied by objective change in the neurological examination (worsening of 0.5 points on the EDSS or worsening by 1.0 or more points on the pyramidal, cerebellar, brainstem or visual functional system scores), not due to fatigue alone and not associated with fever or infection. (NCT00451204)
Timeframe: 24 months
| Intervention | relapses per year (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 0.25 |
| Placebo Capsules Plus Copaxone Injections | 0.37 |
(NCT00451204)
Timeframe: 24 months
| Intervention | probability of relapse at 24 months (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 33.3 |
| Placebo Capsules Plus Copaxone Injections | 42.9 |
Met all criteria for relapse except not confirmed to have increase in EDSS by an independent examiner. (NCT00451204)
Timeframe: 12 months
| Intervention | relapses per year (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 0.33 |
| Placebo Capsules Plus Copaxone Injections | 0.61 |
Met all criteria for relapse except not confirmed to have increase in EDSS by an independent examiner. (NCT00451204)
Timeframe: 24 months
| Intervention | relapses per year (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 0.32 |
| Placebo Capsules Plus Copaxone Injections | 0.46 |
(NCT00451204)
Timeframe: 24 months
| Intervention | probability of relapse event at 24 mo (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 40.5 |
| Placebo Capsules Plus Copaxone Injections | 46.9 |
1 review available for estriol and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration.
Topics: Animals; Central Nervous System Diseases; Dihydrotestosterone; Disease Models, Animal; Encephalomyel | 2012 |
9 other studies available for estriol and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Neuroprotection in Cerebral Cortex Induced by the Pregnancy Hormone Estriol.
Topics: Animals; Atrophy; Cerebral Cortex; Encephalomyelitis, Autoimmune, Experimental; Estriol; Female; Mic | 2023 |
Estrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoimmune demyelinating disease through estrogen receptor alpha (ERalpha).
Topics: Animals; Cells, Cultured; Down-Regulation; Encephalomyelitis, Autoimmune, Experimental; Estriol; Est | 2009 |
Estriol generates tolerogenic dendritic cells in vivo that protect against autoimmunity.
Topics: Animals; Autoimmune Diseases; Biomarkers; Cell Differentiation; Cells, Cultured; Coculture Technique | 2011 |
Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease.
Topics: Animals; CA1 Region, Hippocampal; Cell Adhesion Molecules, Neuronal; Demyelinating Diseases; Disks L | 2012 |
Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease.
Topics: Animals; CA1 Region, Hippocampal; Cell Adhesion Molecules, Neuronal; Demyelinating Diseases; Disks L | 2012 |
Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease.
Topics: Animals; CA1 Region, Hippocampal; Cell Adhesion Molecules, Neuronal; Demyelinating Diseases; Disks L | 2012 |
Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease.
Topics: Animals; CA1 Region, Hippocampal; Cell Adhesion Molecules, Neuronal; Demyelinating Diseases; Disks L | 2012 |
Estrogen receptor alpha mediates estrogen's immune protection in autoimmune disease.
Topics: Adjuvants, Immunologic; Animals; Cytokines; Encephalomyelitis, Autoimmune, Experimental; Estriol; Es | 2003 |
Estriol treatment ameliorates disease in males with experimental autoimmune encephalomyelitis: implications for multiple sclerosis.
Topics: Analysis of Variance; Animals; Cell Culture Techniques; Cytokines; Disease Models, Animal; Encephalo | 2004 |
Estriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosis.
Topics: Animals; Autoimmune Diseases; Brain; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experime | 1999 |
Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains.
Topics: Adoptive Transfer; Animals; Dose-Response Relationship, Immunologic; Drug Administration Schedule; D | 2001 |
A comparison of the effects of melengestrol acetate with a combination of hydrocortisone acetate and medroxyprogesterone acetate and with other steroids in the treatment of experimental alleric encephalomyelitis in Wistar rats.
Topics: Animals; Brain; Drug Combinations; Drug Synergism; Encephalomyelitis, Autoimmune, Experimental; Estr | 1973 |